Africa Rapid Diagnostic Tests (RDT) Market , By Product Type (Consumables and Kits, Instruments and Others), Mode (Professional Rapid Diagnostic Test Product and Over-The-Counter [OTC] Rapid Diagnostic Test Product), Technology (PCR-Based, Flow-Through Assays, Lateral Flow Immunochromatographic Assays, Agglutination Assay, Microfluidics, Substrate Technology and Others), Modality (Laboratory Based Test and Non-Laboratory Based Test), Age Group (Adult and Pediatric), Test Type (Determining Confirmation, Serological Testing and Viral Sequencing), Approach (In-Vitro Diagnostic and Molecular Diagnostic), Specimen (Swab, Blood, Urine, Saliva, Sputum and Others), Application (Infectious Disease Testing, Glucose Monitoring, Cardiology Testing, Oncology Testing, Cardiometabolic Testing, Drugs-of-Abuse Testing, Pregnancy and Fertility Testing, Toxicology Testing, and Others), End User (Hospital and Clinic, Diagnostic Laboratory, Home Care Setting, Research and Academic Institutes and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) – Industry Trends and Forecast to 2030.
Africa Rapid Diagnostic Tests (RDT) Market Analysis and Size
The incidence of rapid diagnostic tests (RDTs) refers to the frequency or rate at which these tests are used or performed. However, it is important to note that the incidence of RDTs can vary greatly depending on the specific disease or condition being tested for, the geographic location, and the healthcare setting. The factors expected to drive the Africa rapid diagnostic tests (RDT) market are the increase in incidence in chronic diseases, rise in geriatric population, technological developments in the rapid diagnostic tests. Moreover, the strategic initiatives by market players and the rise in healthcare expenditure are expected to create opportunities for the Africa rapid diagnostic tests (RDT) market growth.
Data Bridge Market Research analyses that the Africa rapid diagnostic tests (RDT) market, which was USD 1,272.52 million in 2022, is expected to reach USD 2,186.42 million by 2030, and is expected to undergo a CAGR of 7.0% during the forecast period of 2023 to 2030.”Consumables and kits” segment dominates the product type segment of the Africa rapid diagnostic tests (RDT) market owing to the advancements in technology. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Africa Rapid Diagnostic Tests (RDT) Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product Type (Consumables and Kits, Instruments and Others), Mode (Professional Rapid Diagnostic Test Product and Over-The-Counter [OTC] Rapid Diagnostic Test Product), Technology (PCR-Based, Flow-Through Assays, Lateral Flow Immunochromatographic Assays, Agglutination Assay, Microfluidics, Substrate Technology and Others), Modality (Laboratory Based Test and Non-Laboratory Based Test), Age Group (Adult and Pediatric), Test Type (Determining Confirmation, Serological Testing and Viral Sequencing), Approach (In-Vitro Diagnostic and Molecular Diagnostic), Specimen (Swab, Blood, Urine, Saliva, Sputum and Others), Application (Infectious Disease Testing, Glucose Monitoring, Cardiology Testing, Oncology Testing, Cardiometabolic Testing, Drugs-of-Abuse Testing, Pregnancy and Fertility Testing, Toxicology Testing, and Others), End User (Hospital and Clinic, Diagnostic Laboratory, Home Care Setting, Research and Academic Institutes and Others), Distribution Channel (Direct Tender, Retail Sales, and Others)
|
|
Countries Covered
|
South Africa, Nigeria, Ethiopia and Rest of Africa
|
|
Market Players Covered
|
Abbott (U.S.), Danaher (U.S.), Cellex (U.S.), AdvaCare Pharma (China), Access Bio (U.S.), Cardinal Health (U.S.), Bio-Rad Laboratories, Inc. (U.S.), BD (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), bioMérieux SA (France), InBios International, Inc. (U.S.), Gnomegen LLC (U.S.), QIAGEN (Netherlands), Quidel Corporation (U.S.), Chembio Diagnostics Systems, Inc. (U.S.), Siemens Healthcare Gmbh (A Subsidiary Siemens Healthineers AG) (Germany), PerkinElmer Inc. (U.S.), Sekisui Diagnostics (U.S.), Fujirebio (A Subsidiary of H.U. Group) (Japan), PTS Diagnostics (U.S.), LamdaGen Corporation (U.S.), Werfen (Spain), Nova Biomedical (U.S.), Trinity Biotech (Ireland), Sysmex Europe GmbH (A Subsidiary of Sysmex Corporation) (Germany), Luminex Corporation. A DiaSorin Company (U.S.), MEGAKOR DIAGNOSTK GMBH (Germany)
|
|
Market Opportunities
|
|
Market Definition
The rapid diagnostic tests, also called rapid tests, are easy-to-use tests that offer quick results, usually in less than 20 minutes. Unlike other standard and conventional tests, where the diagnosis and sampling are sent to the laboratory, the results obtained from rapid diagnostic test kits are provided at the point of care. The point of care is a place where the patients get cured. The point of care can be a provider's office, a clinic, or a patient's own house. The RDTs are applicable for diagnosing and testing infectious diseases such as COVID-19, cardiology diseases, oncology, pregnancy, fertility testing, toxicology testing, drugs-of-abuse testing, cardiometabolic testing, and glucose monitoring.
Africa Rapid Diagnostic Tests (RDT) Market Dynamics
Drivers
- Increasing Prevalence of Infectious Diseases
The rising burden of infectious diseases worldwide, such as malaria, HIV/AIDS, tuberculosis, and respiratory infections, drives the demand for rapid diagnostic tests. RDTs enable quick and accurate diagnosis, facilitating timely treatment and management of these diseases.
- Growing Demand for Point-of-Care Testing
Point-of-care testing offers the advantage of immediate test results, eliminating the need for laboratory infrastructure and reducing turnaround time. Rapid diagnostic tests are widely used in point-of-care settings, such as clinics, hospitals, and remote areas, where immediate diagnosis is crucial.
- Growing Demand for Personalized Medicine
Personalized medicine focuses on tailoring treatment based on an individual's genetic makeup, lifestyle, and other factors. Rapid diagnostic tests are used to identify specific biomarkers, genetic mutations, or drug resistance patterns, enabling personalized treatment approaches.
Opportunities
- Technological Advancements and Rapid Innovation
Advancements in technology have led to the development of innovative rapid diagnostic tests with improved accuracy, sensitivity, and specificity. For instances, the integration of molecular diagnostic techniques with rapid tests has enhanced their performance and expanded their applications.
- Increasing Awareness and Initiatives for Disease Control
Governments and healthcare organizations are implementing various initiatives to control the spread of infectious diseases. Rapid diagnostic tests play a crucial role in these programs by enabling early detection, effective treatment, and disease surveillance.
Restraints/Challenges
- Limitations in Sensitivity and Specificity
While rapid diagnostic tests offer quick results, they may have limitations in terms of sensitivity and specificity compared to traditional laboratory-based tests. This can lead to false-positive or false-negative results, affecting the accuracy of diagnosis.
-
Regulatory Challenges and Requirements
Rapid diagnostic tests need to meet stringent regulatory requirements to ensure their safety, efficacy, and quality. Obtaining regulatory approvals can be a time-consuming and costly process, which can hinder market growth.
This Africa rapid diagnostic tests (RDT) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Africa rapid diagnostic tests (RDT) market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In June 2021, Bio-Rad Laboratories, Inc. partnered with Seegene, Inc., a global leader in multiplex molecular diagnostics for the clinical development and commercialization of infectious disease molecular diagnostic products. This partnership has allowed the company to increase its sales and product line globally
- In March 2020, Danaher completed the acquisition of the Biopharma business from General Electric. In the future, this business will be called Cytiva and known as a standalone operating company within Danaher's Life Sciences segment. Thus, these acquisition helps the company diversify their segment portfolio
- In December 2020, Quidel Corporation had received emergency approval, from the Food and Drug Administration (FDA), for the Quickvue Sars Rapid Antigen Test for the diagnosis of COVID-19. The approval resulted in increasing Quickvue Sars Rapid Antigen Test distribution to the medical and point-of-care locations and post-marketing approval
Africa Rapid Diagnostic Tests (RDT) Market Scope
The Africa rapid diagnostic tests (RDT) market is segmented on the basis of product type, mode, technology, modality, age group, test type, approach, specimen, application, end user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product Type
- Consumables and Kits
- Instruments
- Others
Mode
- Professional Rapid Diagnostic Test Product
- Over-The-Counter [OTC] Rapid Diagnostic Test Product
Technology
- PCR-Based
- Flow-Through Assays
- Lateral Flow Immunochromatographic Assays
- Agglutination Assa
- Microfluidics
- Substrate Technology
- Others
Modality
- Laboratory Based Test
- Non-Laboratory Based Test
Age Group
- Adult
- Pediatric
Test Type
- Determining Confirmation
- Serological Testing
- Viral Sequencing
Approach
- In-Vitro Diagnostic
- Molecular Diagnostic
Specimen
- Swab
- Blood
- Urine
- Saliva
- Sputum
- Others
Application
- Infectious Disease Testing
- Glucose Monitoring
- Cardiology Testing
- Oncology Testing
- Cardiometabolic Testing
- Drugs-of-Abuse Testing
- Pregnancy and Fertility Testing
- Toxicology Testing
- Others
End User
- Hospital and Clinic
- Diagnostic Laboratory
- Home Care Setting
- Research and Academic Institutes
- Others
Distribution Channel
- Direct Tender
- Retail Sales
- Others
Africa Rapid Diagnostic Tests (RDT) Market Regional Analysis/Insights
The Africa rapid diagnostic tests (RDT) market is analysed and market size insights and trends are provided by country, product type, mode, technology, modality, age group, test type, approach, specimen, application, end user, and distribution channel. as referenced above.
The countries covered in the Africa rapid diagnostic tests (RDT) market report are South Africa, Nigeria, Ethiopia and Rest of Africa
South Africa dominates the Africa rapid diagnostic tests (RDT) market because of the strong presence of major players in the market, rising demand of the rapid diagnostic tests (RDT) products.
South Africa is expected to witness significant growth in the Africa rapid diagnostic tests (RDT) market during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, rise in medical tourism, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The Africa rapid diagnostic tests (RDT) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Africa rapid diagnostic tests (RDT) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on Africa rapid diagnostic tests (RDT) market. The data is available for historic period 2015-2020.
Competitive Landscape and Africa Rapid Diagnostic Tests (RDT) Market Share Analysis
The Africa rapid diagnostic tests (RDT) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Africa rapid diagnostic tests (RDT) market.
Some of the major players operating in the Africa rapid diagnostic tests (RDT) market are:
- Abbott (U.S.)
- Danaher (U.S.)
- Cellex (U.S.)
- AdvaCare Pharma (China)
- Access Bio (U.S.)
- Cardinal Health (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- BD (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- bioMérieux SA (France)
- InBios International, Inc. (U.S.)
- Gnomegen LLC (U.S.)
- QIAGEN (Netherlands)
- Quidel Corporation (U.S.)
- Chembio Diagnostics Systems, Inc. (U.S.)
- Siemens Healthcare Gmbh (A Subsidiary Siemens Healthineers AG) (Germany)
- PerkinElmer Inc. (U.S.)
- Sekisui Diagnostics (U.S.)
- Fujirebio (A Subsidiary of H.U. Group) (Japan)
- PTS Diagnostics (U.S.)
- LamdaGen Corporation (U.S.)
- Werfen (Spain)
- Nova Biomedical (U.S.)
- Trinity Biotech (Ireland)
- Sysmex Europe GmbH (A Subsidiary of Sysmex Corporation) (Germany)
- Luminex Corporation. A DiaSorin Company (U.S.)
- MEGAKOR DIAGNOSTK GMBH (Germany)
SKU-